GSK agreed to acquire Canada-based 35Pharma Inc. for $950 million to expand its pulmonary hypertension pipeline with HS235, an investigational medicine targeting the activin receptor signalling pathway. The acquisition comes as GSK also signed a licensing deal with Frontier Biotechnologies and previously agreed to acquire RAPT Therapeutics for $2...

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting competing offers.

Monteverde & Associates PC is investigating four merger and acquisition transactions involving RAPT Therapeutics, Amicus Therapeutics, Tamboran Resources, and Contango Ore. The firm is encouraging shareholders to act before upcoming votes and tender offer deadlines in March 2026, citing concerns about the proposed deals.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.

Monteverde & Associates PC, a class action law firm, is investigating four merger transactions: Penumbra's sale to Boston Scientific, RAPT Therapeutics' sale to GSK, Nathan's Famous' sale to Smithfield Foods, and Lisata Therapeutics' sale to Smithfield Foods. The firm is seeking shareholders who may have concerns about these deals.